In a study on GBM cell lines, samples that carried the intact RB1 gene showed response to palbociclib, a selective inhibitor of CDK4 and CDK6 cyclin-dependent kinases, while samples with homozygous deletions or mutations causing loss of the Rb protein had no palbociclib response [21,22]. This evidence concerns the gene CDK4 and glioblastoma.